Project Grant R34CA301070
Award Date 7/6/26
Completion Date 6/30/29
Dollars Obligated $321K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Baylor College of Medicine a $882,470 Research Specialist (Clinician Scientist) Award under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2030. The award supports clinical leadership and trial development services focused on pediatric and adolescent cancer patients with hematologic malignancies. The primary deliverables include establishment and facilitation of a...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $533,245 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on June 1, 2026, with a completion date of May 30, 2031. This research project aims to develop therapeutic strategies to eradicate leukemia-initiating cells (LICs) in acute myeloid leukemia (AML) by investigating protein glutathionylation as a regulatory mechanism for oxidative...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $731,503 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Cause and Prevention Research program (CFDA 93.393) for a five-year randomized controlled trial (RCT) beginning June 1, 2026 and concluding May 31, 2031. The award funds a clinical research initiative developing and testing Brief Behavioral Activation for Older Adult Cancer Survivors (BBA-OACS), an evidence-based psychotherapy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Ann & Robert H Lurie Children's Hospital of Chicago a $651,859 Project Grant on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and evaluate #AYAOSM (The AYA Oncology Self-Care Movement), an influencer-driven social media intervention designed to improve oral chemotherapy adherence in adolescents and young adults (AYAs) with acute lymphoblastic leukemia. Prior...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $744,511 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. The grant funds fundamental research to characterize and target hematopoietic stem and progenitor cell-like (HSPC-like) blasts in high-risk acute leukemias, including acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-lineage...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a Project Grant of $411,334 under the Cancer Treatment Research program (CFDA 93.395), with an award date of March 18, 2026 and completion date of February 29, 2028. This research project will quantify associations between rest-activity rhythm parameters derived from actigraphy data and persistent cancer-related fatigue using data from the Harvest for Health clinical trial. The study...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded $276,545 to The Children's Hospital of Philadelphia Research Institute on June 8, 2026, for the development of genomic risk prediction models for T-cell malignancies. The project, which runs through May 31, 2031, addresses a critical gap in clinical care by developing and validating risk stratification tools for T-cell acute lymphoblastic leukemia (T-ALL) and...